Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Home
Researchers
Organisations
Research output
Prizes
Student theses
Activities
Projects
Press/Media
Datasets
Equipment
Search by expertise, name or affiliation
Empagliflozin and progression of kidney disease in type 2 diabetes
EMPA-REG OUTCOME Investigators
Bar-Ilan University - Azrieli Faculty of Medicine
University of Würzburg
Yale University
George Washington University
University of Toronto
Boehringer Ingelheim GmbH
Boehringer Ingelheim Norway KS
Research output
:
Contribution to journal
›
Article
›
peer-review
2655
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Empagliflozin and progression of kidney disease in type 2 diabetes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Kidney Disease Progression
100%
Empagliflozin
100%
Type 2 Diabetic Patients
27%
Placebo Groups
27%
Placebo
18%
Serum Creatinine Level
18%
Renal Replacement Therapy
18%
Albuminuria
18%
High Risk
9%
Low Dose Rate
9%
Diabetes
9%
Confidence Interval
9%
Hazard Ratio
9%
Clinically Significant
9%
Renal Disease
9%
Nephropathy
9%
Relative Risk
9%
Once-daily
9%
Cardiovascular Events
9%
Major Adverse Cardiovascular Events
9%
Between-group Difference
9%
High Cardiovascular Risk
9%
Estimated Glomerular Filtration Rate
9%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
9%
Microalbuminuria
9%
Body Surface Area
9%
Renal Events
9%
Disease Rate
9%
Renal Outcome
9%
Slow Progression
9%
Nephropathy Progression
9%
Adverse Cardiovascular Events
9%
Renal Effects
9%
Adverse Events Profile
9%
Vascular Outcomes
9%
EMPA-REG OUTCOME Trial
9%
Relative Risk Reduction
9%
Impaired Kidney Function
9%
Adverse Renal Event
9%
Trial Population
9%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Nephropathy
100%
Empagliflozin
100%
Placebo
45%
Patient with Type 2 Diabetes
27%
Cardiovascular System
18%
Creatinine
18%
Renal Replacement Therapy
18%
Albuminuria
18%
Cardiovascular Disease
9%
Hazard Ratio
9%
Adverse Event
9%
Kidney Function
9%
Glomerular Filtration Rate
9%
Cardiovascular Risk
9%
Diabetes
9%
Macroalbuminuria
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Body Surface
9%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
9%
Relative Risk Reduction
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Kidney Disease
100%
Empagliflozin
100%
Placebo
45%
Replacement Therapy
18%
Creatinine
18%
Albuminuria
18%
Cardiovascular Disease
9%
Adverse Event
9%
Cardiovascular Risk
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Macroalbuminuria
9%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
9%